FY 2021 Appropriations Provides FDA Healthy Boost – Plus More COVID-19 Funds
Budget authority increase for medical product safety is coupled with additional funds for coronavirus countermeasure development and advanced manufacturing.
You may also be interested in...
Unannounced facility visits also were to start again in China, but FDA Commissioner Robert Califf said they have been delayed by the COVID-19 outbreak in the country.
The House Appropriations Committee also does not want the agency to become too dependent on alternative inspection tools.
Multiple congressional offices attended a briefing on GDUFA III with FDA and industry officials, suggesting plans for the must-pass bill already are in the works.